Walvax BioTech (300142) — Strategic Asset Allocation Index
Walvax BioTech (300142) has a Strategic Asset Allocation Index of 29.7% as of June 2023. Strategic assets (PP&E of CN¥3.40 Billion plus long-term investments of CN¥-) total CN¥3.40 Billion, measured against net assets of CN¥11.47 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See debt-free asset ratio of Walvax BioTech to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Walvax BioTech Strategic Asset Allocation Index (2007–2022)
This chart shows how Walvax BioTech's Strategic Asset Allocation Index has evolved across 16 annual periods from 2007 to 2022. As of June 2023, the index stands at 29.7%, representing strategic assets of CN¥3.40 Billion against net assets of CN¥11.47 Billion CNY. For live market cap and overall valuation, see market value of Walvax BioTech.
Annual Strategic Asset Allocation Index for Walvax BioTech (2007–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Walvax BioTech from 2007 to 2022, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Walvax BioTech net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 28.8% | CN¥3.16 Billion | CN¥3.16 Billion | CN¥- | CN¥10.99 Billion | ▲ +2.7 pp |
| 2021 | 26.0% | CN¥2.60 Billion | CN¥2.60 Billion | CN¥- | CN¥10.00 Billion | ▲ +5.8 pp |
| 2020 | 20.3% | CN¥1.59 Billion | CN¥1.59 Billion | CN¥- | CN¥7.85 Billion | ▼ -19.5 pp |
| 2019 | 39.7% | CN¥2.25 Billion | CN¥1.39 Billion | CN¥862.27 Million | CN¥5.67 Billion | ▲ +0.7 pp |
| 2018 | 39.0% | CN¥2.05 Billion | CN¥1.30 Billion | CN¥751.56 Million | CN¥5.26 Billion | ▼ -13.1 pp |
| 2017 | 52.0% | CN¥1.85 Billion | CN¥1.52 Billion | CN¥326.89 Million | CN¥3.56 Billion | ▲ +3.9 pp |
| 2016 | 48.2% | CN¥1.70 Billion | CN¥1.36 Billion | CN¥335.51 Million | CN¥3.52 Billion | ▼ -21.9 pp |
| 2015 | 70.0% | CN¥2.12 Billion | CN¥1.40 Billion | CN¥721.86 Million | CN¥3.02 Billion | ▲ +30.0 pp |
| 2014 | 40.1% | CN¥1.29 Billion | CN¥1.29 Billion | CN¥- | CN¥3.21 Billion | ▼ -3.4 pp |
| 2013 | 43.4% | CN¥1.28 Billion | CN¥1.28 Billion | CN¥- | CN¥2.94 Billion | ▲ +15.0 pp |
| 2012 | 28.5% | CN¥902.13 Million | CN¥902.13 Million | CN¥- | CN¥3.17 Billion | ▲ +11.5 pp |
| 2011 | 17.0% | CN¥461.04 Million | CN¥461.04 Million | CN¥- | CN¥2.71 Billion | ▲ +2.9 pp |
| 2010 | 14.1% | CN¥360.00 Million | CN¥360.00 Million | CN¥- | CN¥2.55 Billion | ▼ -44.7 pp |
| 2009 | 58.8% | CN¥102.68 Million | CN¥102.68 Million | CN¥- | CN¥174.69 Million | ▼ -45.2 pp |
| 2008 | 104.0% | CN¥102.25 Million | CN¥102.25 Million | CN¥- | CN¥98.36 Million | ▼ -419.9 pp |
| 2007 | 523.8% | CN¥92.49 Million | CN¥92.49 Million | CN¥- | CN¥17.66 Million | — |